Rationale for the use of multifunctional drugs as neuroprotective agents for glaucoma

Neural Regeneration Research

Volumn 7, Issue 4, 2012, Pages 313-318

  Fang, Jiahua ^a   Jiang, Fagang ^b   Li, Jingbo ^a   Zhu, Yanhua ^a  

^a YANGTZE UNIVERSITY   (China)

^b HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Glaucoma; Multifunctional drugs; Neurodegenerative disease; Neuroprotection; Retinal ganglion cells; Reviews

Indexed keywords

ACETYLCHOLINESTERASE; AMYLOID BETA PROTEIN; EPIGALLOCATECHIN GALLATE; GLUTAMIC ACID; IONOTROPIC RECEPTOR; MEMANTINE; NEURONAL NITRIC OXIDE SYNTHASE; NEUROPROTECTIVE AGENT; NEUROTROPHIN; TACRINE DERIVATIVE; VOLTAGE GATED CALCIUM CHANNEL;

CALCIUM CELL LEVEL; CELL DEATH; DRUG TARGETING; EXCITOTOXICITY; GLAUCOMA; HUMAN; INTRAOCULAR PRESSURE; NEUROPROTECTION; OXIDATIVE STRESS; RETINA GANGLION CELL; REVIEW;

EID: 84863250848     PISSN: 16735374     EISSN: 18767958     Source Type: Journal    
DOI: 10.3969/j.issn.1673-5374.2011.04.013     Document Type: Review

References (66)

1. Quigley HA. Glaucoma. Lancet. 2011;377:1367-1377.
2. Cheung W, Guo L, Cordeiro MF. Neuroprotection in glaucoma: drug-based approaches. Optom Vis Sci. 2008;85:406-416.
3. Dahlmann-Noor AH, Vijay S, Limb GA, et al. Strategies for optic nerve rescue and regeneration in glaucoma and other optic neuropathies. Drug Discov Today. 2010;15:287-299.
4. Chidlow G, Wood JP, Casson RJ. Pharmacological neuroprotection for glaucoma. Drugs. 2007;67:725-759.
5. Weinreb RN. Glaucoma neuroprotection: What is it? Why is it needed? Can J Ophthalmol. 2007;42:396-398.
6. Danesh-Meyer HV. Neuroprotection in glaucoma: recent and future directions. Curr Opin Ophthalmol. 2011;22:78-86.
7. Osborne NN. Recent clinical findings with memantine should not mean that the idea of neuroprotection in glaucoma is abandoned. Acta Ophthalmol. 2009;87:450-454.
8. Danesh-Meyer HV, Levin LA. Neuroprotection: extrapolating from neurologic diseases to the eye. Am J Ophthalmol. 2009;148: 186-191.
9. Youdim MB, Buccafusco JJ. Multi-functional drugs for various CNS targets in the treatment of neurodegenerative disorders. Trends Pharmacol Sci. 2005;26:27-35.
10. Geldenhuys WJ, Youdim MB, Carroll RT, et al. The emergence of designed multiple ligands for neurodegenerative disorders. Prog Neurobiol. 2011;94:347-359.
11. Van der Schyf CJ, Youdim MB. Multifunctional drugs as neurotherapeutics. Neurotherapeutics. 2009;6:1-3.
12. Cavalli A, Bolognesi ML, Minarini A, et al. Multi-target-directed ligands to combat neurodegenerative diseases. J Med Chem. 2008;51:347-372.
13. Valenti DA. Alzheimer's disease and glaucoma: imaging the biomarkers of neurodegenerative disease. Int J Alzheimers Dis. 2011;2010:793-931.
14. Gupta N, Yucel YH. Glaucoma as a neurodegenerative disease. Curr Opin Ophthalmol. 2007;18:110-114.
15. Bayer AU, Keller ON, Ferrari F, et al. Association of glaucoma with neurodegenerative diseases with apoptotic cell death: Alzheimer's disease and Parkinson's disease. Am J Ophthalmol. 2002;133: 135-137.
16. McKinnon SJ. Glaucoma: ocular Alzheimer's disease? Front Biosci. 2003;8:s1140-1156.
17. McKinnon SJ, Lehman DM, Kerrigan-Baumrind LA, et al. Caspase activation and amyloid precursor protein cleavage in rat ocular hypertension. Invest Ophthalmol Vis Sci. 2002;43: 1077-1087.
18. Baltmr A, Duggan J, Nizari S, et al. Neuroprotection in glaucoma Is there a future role? Exp Eye Res. 2010;91:554-566.
19. Le A, Mukesh BN, McCarty CA, et al. Risk factors associated with the incidence of open-angle glaucoma: the visual impairment project. Invest Ophthalmol Vis Sci. 2003;44:3783-3789.
20. Zimmermann GR, Lehar J, Keith CT. Multi-target therapeutics: when the whole is greater than the sum of the parts. Drug Discov Today. 2007;12:34-42.
21. Morphy R, Rankovic Z. Designed multiple ligands. An emerging drug discovery paradigm. J Med Chem. 2005;48:6523-6543.
22. Yang K, Bai H, Ouyang Q, et al. Finding multiple target optimal intervention in disease-related molecular network. Mol Syst Biol. 2008;4:228.
23. Bolognesi ML, Matera R, Minarini A, et al. Alzheimer's disease: new approaches to drug discovery. Curr Opin Chem Biol. 2009;13:303-308.
24. Witt A, Macdonald N, Kirkpatrick P. Memantine hydrochloride. Nat Rev Drug Discov. 2004;3:109-110.
25. Noorbakhsh F, Overall CM, Power C. Deciphering complex mechanisms in neurodegenerative diseases: the advent of systems biology. Trends Neurosci. 2009;32:88-100.
26. Stahl SM. Multifunctional drugs: a novel concept for psychopharmacology. CNS Spectr. 2009;14:71-73.
27. Weinreb O, Mandel S, Bar-Am O, et al. Multifunctional neuroprotective derivatives of rasagiline as anti-Alzheimer's disease drugs. Neurotherapeutics. 2009;6:163-174.
28. Sucher NJ, Lipton SA, Dreyer EB. Molecular basis of glutamate toxicity in retinal ganglion cells. Vision Res. 1997;37:3483-3493.
29. Cho KJ, Kim JH, Park HY, et al. Glial cell response and iNOS expression in the optic nerve head and retina of the rat following acute high IOP ischemia-reperfusion. Brain Res. 2011;1403: 67-77.
30. Kang JH, Wiggs JL, Rosner BA, et al. Endothelial nitric oxide synthase gene variants and primary open-angle glaucoma: interactions with sex and postmenopausal hormone use. Invest Ophthalmol Vis Sci. 2010;51:971-979.
31. Toda N, Nakanishi-Toda M. Nitric oxide: ocular blood flow, glaucoma, and diabetic retinopathy. Prog Retin Eye Res. 2007;26:205-238.
32. Park SH, Kim JH, Kim YH, et al. Expression of neuronal nitric
33. Libby RT, Howell GR, Pang IH, et al. Inducible nitric oxide synthase, Nos2, does not mediate optic neuropathy and retinopathy in the DBA/2J glaucoma model. BMC Neurosci. 2007;8:108.
34. Melena J, Osborne NN. Voltage-dependent calcium channels in the rat retina: involvement in NMDA-stimulated influx of calcium. Exp Eye Res. 2001;72:393-401.
35. Brandt SK, Weatherly ME, Ware L, et al. Calcium preconditioningtriggers neuroprotection in retinal ganglion cells. Neuroscience, 2011, 172: 387-397.
36. Thoreson WB, Witkovsky P. Glutamate receptors and circuits in the vertebrate retina. Prog Retin Eye Res. 1999;18: 765-810.
37. Tezel G. The immune response in glaucoma: A perspective on the roles of oxidative stress. Exp Eye Res. 2011;93:178-186.
38. Tezel G. Oxidative stress in glaucomatous neurodegeneration: mechanisms and consequences. Prog Retin Eye Res. 2006;25: 490-513.
39. Tatton W, Chen D, Chalmers-Redman R, et al. Hypothesis for a common basis for neuroprotection in glaucoma and Alzheimer's disease: anti-apoptosis by alpha-2-adrenergic receptor activation. Surv Ophthalmol. 2003;48 Suppl 1:S25-37.
40. Sakamoto K, Ohki K, Saito M, et al. Histological protection by donepezil against neurodegeneration induced by ischemia-reperfusion in the rat retina. J Pharmacol Sci. 2010;112: 327-335.
41. Guo L, Salt TE, Luong V, et al. Targeting amyloid-beta in glaucoma treatment. Proc Natl Acad Sci U S A. 2007;104: 13444-13449.
42. Johnson EC, Guo Y, Cepurna WO, et al. Neurotrophin roles in retinal ganglion cell survival: lessons from rat glaucoma models. Exp Eye Res. 2009;88:808-815.
43. Kido N, Tanihara H, Honjo M, et al. Neuroprotective effects of brain-derived neurotrophic factor in eyes with NMDA-induced neuronal death. Brain Res. 2000;884:59-67.
44. Colafrancesco V, Parisi V, Sposato V, et al. Ocular application of nerve growth factor protects degenerating retinal ganglion cells in a rat model of glaucoma. J Glaucoma. 2011;20:100-108.
45. Lambiase A, Aloe L, Centofanti M, et al. Experimental and clinical evidence of neuroprotection by nerve growth factor eye drops: Implications for glaucoma. Proc Natl Acad Sci U S A. 2009;106: 13469-13474.
46. Demetriades AM. Gene therapy for glaucoma. Curr Opin Ophthalmol. 2011;22:73-77.
47. Fan BJ, Wiggs JL. Glaucoma: genes, phenotypes, and new directions for therapy. J Clin Invest. 2010;120:3064-3072.
48. Jeun M, Jeoung JW, Moon S, et al. Engineered superparamagnetic Mn0.5Zn0.5Fe2O4 nanoparticles as a heat shock protein induction agent for ocular neuroprotection in glaucoma. Biomaterials. 2011;32:387-394.
49. Seki M, Soussou W, Manabe S, et al. Protection of retinal ganglion cells by caspase substrate-binding peptide IQACRG from N-methyl-D-aspartate receptor-mediated excitotoxicity. Invest Ophthalmol Vis Sci. 2010;51:1198-1207.
50. Zhang B, Safa R, Rusciano D, et al. Epigallocatechin gallate, an active ingredient from green tea, attenuates damaging influences to the retina caused by ischemia/reperfusion. Brain Res. 2007; 1159:40-53.
51. Xie D, Liu G, Zhu G, et al. (-)-Epigallocatechin-3-gallate protects cultured spiral ganglion cells from H2O2-induced oxidizing damage. Acta Otolaryngol. 2004;124:464-470.
52. Lee JH, Song DK, Jung CH, et al. (-)-Epigallocatechin gallate attenuates glutamate-induced cytotoxicity via intracellular Ca modulation in PC12 cells. Clin Exp Pharmacol Physiol. 2004;31: 530-536.
53. Aktas O, Prozorovski T, Smorodchenko A, et al. Green tea epigallocatechin-3-gallate mediates T cellular NF-kappa B inhibition and exerts neuroprotection in autoimmune encephalomyelitis. J Immunol. 2004;173:5794-5800.
54. Hou RR, Chen JZ, Chen H, et al. Neuroprotective effects of (-)-epigallocatechin-3-gallate (EGCG) on paraquat-induced apoptosis in PC12 cells. Cell Biol Int. 2008;32:22-30.
55. Pang YP, Quiram P, Jelacic T, et al. Highly potent, selective, and low cost bis-tetrahydroaminacrine inhibitors of acetylcholinesterase. Steps toward novel drugs for treating Alzheimer's disease. J Biol Chem. 1996;271:23646-23649.
56. Liu YW, Luo JL, Ren H, et al. Inhibition of NMDA-gated ion channels by bis(7)-tacrine: whole-cell and single-channel studies. Neuropharmacology. 2008;54:1086-1094.
57. Luo J, Li W, Liu Y, et al. Novel dimeric bis(7)-tacrine proton-dependently inhibits NMDA-activated currents. Biochem Biophys Res Commun. 2007;361:505-509.
58. Li W, Xue J, Niu C, et al. Synergistic neuroprotection by bis(7)-tacrine via concurrent blockade of N-methyl-D-aspartate receptors and neuronal nitric-oxide synthase. Mol Pharmacol. 2007;71:1258-1267.
59. Fu H, Li W, Lao Y, et al. Bis(7)-tacrine attenuates beta amyloid-induced neuronal apoptosis by regulating L-type calcium channels. J Neurochem. 2006;98:1400-1410.
60. Li W, Mak M, Jiang H, et al. Novel anti-Alzheimer's dimer Bis(7)-cognitin: cellular and molecular mechanisms of neuroprotection through multiple targets. Neurotherapeutics. 2009;6:187-201.
61. Fang JH, Wang XH, Xu ZR, et al. Neuroprotective effects of bis(7)-tacrine against glutamate-induced retinal ganglion cells damage. BMC Neurosci. 2010;11:31.
62. Zhang ZH, Liu YW, Jiang FG, et al. Bis(7)-tacrine protects retinal ganglion cells against excitotoxicity via NMDA receptor inhibition. Int J Ophthalmol. 2011;4:125-130.
63. Dreyer EB. A proposed role for excitotoxicity in glaucoma. J Glaucoma. 1998;7:62-67.
64. Alward WL. Medical management of glaucoma. N Engl J Med. 1998;339:1298-1307.
65. Comparison of glaucomatous progression between untreatedpatients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. Collaborative Normal-Tension Glaucoma Study Group. Am J Ophthalmol. 1998;126:487-497.
66. Bakalash S, Kipnis J, Yoles E, et al. Resistance of retinal ganglion cells to an increase in intraocular pressure is immune-dependent. Invest Ophthalmol Vis Sci. 2002;43:2648-2653.